(RTTNews) - Shares of AnaptysBio, Inc. (ANAB) are down over 30% as the clinical-stage biotechnology company announced that its Phase 2b trial of ANB032 in Atopic Dermatitis did not meet the primary and secondary endpoints.
In the Phase 2b trial, dubbed ARISE-AD, ANB032 was tested as monotherapy in 201 moderate-to-severe Atopic Dermatitis patients in the U.S., Canada, Europe, Australia, and New Zealand.
During the 14th Week assessment, the trial did not achieve the primary endpoint of at least a 75% improvement from baseline in Eczema Area and Severity Index score (EASI-75), or any of the secondary endpoints, including EASI-90, or a 4-point reduction in itch severity as measured by the peak Pruritus Numerical Rating Scale (PNRS) versus placebo.
Further, the company has decided to discontinue the ANB032 study and divert its funding to the development of other pipeline products.
The other ongoing programs include:
-- Rosnilimab in a Phase 2b trial for rheumatoid arthritis (RA), with top-line data expected in February 2025.
-- A phase II trial of Rosnilimab for ulcerative colitis is also ongoing, with top-line Week 12 data anticipated in the first quarter of 2026.
-- ANB033, being developed for the treatment of T cell-mediated inflammatory and autoimmune diseases, is in a Phase 1 trial in healthy volunteers.
Currently, ANAB's trading is at $15.25, down by 33.95 percent on Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
